We exist to improve the lives
of everyone affected by epilepsy

Epilepsy Today

Fitness to practice medicine impaired, says medical tribunal looking into Dr Valerie Murphy in charge of Connor Sparrowhawk’s care

14 Nov 2017

Dr Valerie Murphy’s fitness to practice medicine has been found to be impaired by misconduct. This was decided by a medical practitioners tribunal on Sunday 12 October.

Dr Murphy was in charge of the care of 18-year-old Connor Sparrowhawk at an NHS facility in 2013. Connor, who had epilepsy, learning disabilities and autism, died after having a seizure in the bath.

Welsh government shows support for children with conditions like epilepsy in schools

7 Nov 2017

The Welsh government has supported an amendment to its new bill for additional learning needs in children.

A number of organisations have pushed for the Additional Learning Needs and Education Tribunal Bill (ALN Bill) in Wales to include medical conditions such as epilepsy. These include Epilepsy Action Cymru, Diabetes UK and The Royal College of Paediatrics and Child Health (RCPCH).

Epilim Chrono 200mg ongoing shortage in UK

2 Nov 2017

Some pharmacists are having problems getting hold of Epilim Chrono 200mg tablets due to an ongoing shortage. Sanofi are currently out of stock of these tablets. They expect to send more stock to wholesalers around 13 November 2017.

Sanofi last sent supplies of Epilim Chrono 200mg to wholesalers on 24 October, so some may still have stock. Your pharmacist can contact Sanofi customer services to find out which wholesalers have had deliveries.

All other doses of Epilim Chrono are in stock.

Parliamentary debate suggests a public inquiry should be held into sodium valproate “scandal”

24 Oct 2017

A parliamentary debate was held in the House of Commons in London on 19 October. At the debate, MPs discussed sodium valproate and foetal anticonvulsant syndrome.

Norman Lamb, chair of the Science and Technology Committee, led the debate. He said that there had been “systematic failure” to warn women of the risks of valproate since the 1970s.

Lacosamide epilepsy medicine approved for use in children over 4 years old with focal-onset seizures

29 Sep 2017

Pharmaceutical company UCB’s lacosamide epilepsy medicine, known as VIMPAT, has been approved by the European Commission for use in children over 4 years old in Europe.

The lacosamide medicine was approved in September for use on its own or alongside other medicines to treat focal-onset seizures. It was previously approved for use in teenagers over 16 years old and adults in Europe.